{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:55:00Z","timestamp":1793202900614,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2023B01J1007"],"award-info":[{"award-number":["2023B01J1007"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2023B03J0154"],"award-info":[{"award-number":["2023B03J0154"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070612"],"award-info":[{"award-number":["82070612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170612"],"award-info":[{"award-number":["82170612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170364"],"award-info":[{"award-number":["82170364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10302204"],"award-info":[{"award-number":["2018ZX10302204"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e32730","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:25:26Z","timestamp":1718148326000},"page":"e32730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level"],"prefix":"10.1016","volume":"10","author":[{"given":"Lili","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingliang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-4416","authenticated-orcid":false,"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.heliyon.2024.e32730_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32730_bib3","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32730_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32730_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with Peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new Switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global Epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"issue":"9491","key":"10.1016\/j.heliyon.2024.e32730_bib8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32730_bib11","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e32730_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113888","article-title":"Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e32730_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/JHC.S283840","article-title":"Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma","volume":"9","author":"Chavez-Tapia","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32730_bib14","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/s41598-020-62609-4","article-title":"Association between hepatitis B virus infection and metabolic syndrome in Southwest China: a Cross-sectional study","volume":"10","author":"Yan","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32730_bib15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32730_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/apt.12874","article-title":"Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B","volume":"40","author":"Hsiang","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32730_bib17","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jfma.2022.07.013","article-title":"Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B","volume":"121","author":"Huang","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32730_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00535-019-01594-6","article-title":"Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population","volume":"54","author":"Wang","year":"2019","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32730_bib19","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.heliyon.2024.e32730_bib20","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2147\/DMSO.S369824","article-title":"Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective Cohort study","volume":"15","author":"Wang","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.heliyon.2024.e32730_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13830","article-title":"Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study","author":"Yun","year":"2022","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e32730_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/DMSO.S351492","article-title":"MAFLD is associated with the risk of liver fibrosis and inflammatory activity in HBeAg-negative CHB patients","volume":"15","author":"Chen","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/1751-2980.12687","article-title":"Guidelines of prevention and treatment for alcoholic liver disease (2018, China)","volume":"20","author":"Li","year":"2019","journal-title":"J Dig Dis"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32730_bib26","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.40263","article-title":"Noninvasive diagnosis of hepatic steatosis using fat attenuation parameter measured by FibroTouch and a new Algorithm in CHB patients","volume":"16","author":"Deng","year":"2016","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.heliyon.2024.e32730_bib27","article-title":"Transient elastography and Ultrasonography: Optimal Evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B Concurrent with nonalcoholic fatty liver disease","volume":"2019","author":"Zhang","year":"2019","journal-title":"BioMed Res. Int."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32730_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7150\/ijms.42248","article-title":"ACSL1 affects triglyceride levels through the PPAR\u03b3 Pathway","volume":"17","author":"Li","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib29","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.1152\/ajpendo.00112.2006","article-title":"Overexpression of acyl-CoA synthetase-1 increases lipid deposition in hepatic (HepG2) cells and rodent liver in vivo","volume":"291","author":"Parkes","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e32730_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32730_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jvh.13452","article-title":"Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis","volume":"28","author":"Campbell","year":"2021","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/hep.30083","article-title":"Diabetes, plasma glucose, and Incidence of fatty liver, cirrhosis, and liver cancer: a Prospective study of 0.5 million People","volume":"68","author":"Pang","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hep.32178","article-title":"Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome\/multivesicular body axis","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e32730_bib34","article-title":"The relationship between HMGB1 and autophagy in the pathogenesis of diabetes and its complications","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib35","first-page":"99","article-title":"[Impact of liver steatosis on the curative effect of pegylated interferon-alpha-2a in patients with chronic hepatitis B]","volume":"23","author":"Xu","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"40","key":"10.1016\/j.heliyon.2024.e32730_bib36","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3748\/wjg.v17.i40.4517","article-title":"Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B","volume":"17","author":"Ate\u015f","year":"2011","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32730_bib37","first-page":"285","article-title":"[Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B]","volume":"20","author":"Shi","year":"2012","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32730_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.mcg.0000225586.78330.60","article-title":"Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection","volume":"41","author":"Cindoruk","year":"2007","journal-title":"J. Clin. Gastroenterol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32730_bib39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/apt.14960","article-title":"Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study","volume":"48","author":"Kuo","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e32730_bib40","article-title":"Metabolic syndrome, nonalcoholic fatty liver disease, and chronic hepatitis B: a Narrative review","author":"Diao","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32730_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/apt.15575","article-title":"Systematic review: chronic viral hepatitis and metabolic derangement","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e32730_bib42","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jfma.2021.10.014","article-title":"Hepatic steatosis and development of type 2 diabetes: impact of chronic hepatitis B and viral specific factors","volume":"121","author":"Yu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32730_bib43","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s11010-021-04143-z","article-title":"Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress","volume":"477","author":"Liu","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32730_bib44","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.14309\/ajg.0000000000000400","article-title":"Phase transition is Infrequent among North American adults with e-antigen-negative chronic hepatitis B and low-level viremia","volume":"114","author":"Zhou","year":"2019","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32730_bib45","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/liv.15252","article-title":"Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia","volume":"42","author":"Yang","year":"2022","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32730_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00044011-199611010-00005","article-title":"Effect of interferon on blood lipids","volume":"11","author":"Malaguarnera","year":"1996","journal-title":"Clin. Drug Invest."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32730_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(05)80675-0","article-title":"Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis","volume":"16","author":"Ruiz-Moreno","year":"1992","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32730_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/emboj\/19.5.819","article-title":"Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis","volume":"19","author":"Istvan","year":"2000","journal-title":"Embo j"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32730_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/jir.2009.0085","article-title":"Association between capacity of interferon-alpha production and metabolic parameters","volume":"30","author":"Tominaga","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32730_bib50","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ajpath.2021.03.006","article-title":"Type I interferon signaling Accelerates liver regeneration by metabolic modulation in Noninfectious conditions","volume":"191","author":"Wu","year":"2021","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32730_bib51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3748\/wjg.v13.i7.1060","article-title":"Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice","volume":"13","author":"Ma","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e32730_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1091786","article-title":"Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU\/ml treated with pegylated interferon[J]","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024087619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024087619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:52:26Z","timestamp":1790542346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024087619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024087619"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32730","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e32730"}}